Vabysmo Improves Vision in Underrepresented DME Populations
A recent Phase IV clinical trial named ELEVATUM has shown promising results for Vabysmo, a medication used to treat...
Jon Napitupulu
Oncoprism® Earns Medicare Coverage: Predicting Immunotherapy Response
Cofactor Genomics, a clinical-stage company focused on RNA analysis for precision medicine, has received national coverage from Medicare contractor...
Vertex Unveils Suzетrigine as First-in-Class Pain Inhibitor at ASAnesthesia
Vertex Pharmaceuticals will unveil its pivotal Phase 3 data for suzetrigine, a potential non-opioid treatment for moderate-to-severe acute pain,...
Gilead and Merck Announce Phase 2 Islatravir and Lenacapavir Data
Gilead Sciences and Merck have announced positive results from a Phase 2 clinical trial investigating a novel combination therapy...
Resposne Pharmaceuticals Initates RDX-002 Phase 2 Study Weight management
Response Pharmaceuticals, a clinical-stage company specializing in weight management and metabolic health, has begun enrolling participants in a Phase...
Terray Therapeutics Raises $120M in Series B Funding
Terray Therapeutics, a biotechnology company revolutionizing small molecule drug development, has secured $120 million in Series B funding. This...
Verastem Presents Positive Updated Data for Atutometinib
Verastem Oncology, a company dedicated to developing cancer treatments, has released promising data from its Phase 2 RAMP 201...
Gilead Reveals Remarkable Findings in HIV Prevention Trial: Encouraging News for a Devastating Disease
Gilead Sciences has reported promising data from its Phase 3 PURPOSE 2 trial, demonstrating the efficacy and safety of...
Airsupra Reduces Severe Asthma Attacks: A Game-Changer for Patients
A clinical trial (BATURA) has shown the efficacy of AstraZenaca’s AIRSUPRA (albuterol/budesonide) in reducing the risk of severe asthma...
New HPV Vaccine Trial Gives Hope to Cancer Patients
TheraVectys, a biotechnology company specializing in lentiviral vector-based vaccines and immunotherapies, has begun enrolling patients in a Phase I/IIa...